EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Diagnostic Accuracy of PSMA-PET/CT vs. mpMRI in Primary Staging of Intermediate- and High-Risk Prostate Cancer

Vanessa Talavera Cobo iD, Carlos Andres Yánez Ruiz, Mario Daniel Tapia Tapia, Andres Calva Lopez iD, Carmina Alejandra Muñoz Bastidas iD, Francisco Javer Ancizu Marckert, Marcos Torres Roca, Luis Labairu Huerta iD, Daniel Sanchez Zalabardo iD, Fernando Jose Diez-Caballero Alonso, Francisco Guillen-Grima iD, Jose E Robles García iD und 1 weitere

Medical Sciences · 2026

DOI: 10.3390/medsci14010064 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Medical Sciences, 2026. Verfasst von Vanessa Talavera Cobo und 12 weiteren Autor:innen. Beteiligte Einrichtung: Urology Department, Clínica Universidad de Navarra, 31008 Pamplona, Spain. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Positron Emission Tomography Computed Tomography, Glutamate Carboxypeptidase II, Antigens, Surface. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Prostate-specific membrane antigen (PSMA) is markedly overexpressed in prostate cancer (PCa), and there is growing evidence to support its usefulness in initial diagnostic assessments. This study compares the diagnostic performance of PSMA positron emission tomography/computed tomography (PET/CT) and magnetic resonance imaging (mpMRI) in evaluating seminal vesicle invasion (SVI), extraprostatic extension (EPE), and pelvic lymph node involvement before radical prostatectomy.

Methods

A retrospective, single-institution analysis was performed. From a cohort of 325 patients who underwent radical prostatectomy between June 2022 to November 2024, 85 had undergone preoperative PSMA PET/CT for intermediate- and high-risk disease at biopsy, forming our study group. Two blinded specialists, one in radiology and one in nuclear medicine, independently interpreted the scans, using histopathological results as the reference standard. The primary outcome was diagnostic accuracy for T- and N-stage classification, while the secondary outcomes included the correct identification of the index lesion and comparative performance for each modality.

Results

The study cohort comprised patients with intermediate-to-high-risk prostate cancer (median age: 66 years; median PSA level: 11.6 ng/mL; median PSA density: 0.3 ng/mL/cm3). Forty-eight patients presented with an ISUP grade of 3 or higher on biopsy. PSMA PET/CT was more sensitive than MRI for detecting EPE (72.2% vs. 46.9%) and nodal metastases (91.7% vs. 8.3%). Furthermore, PSMA PET/CT demonstrated significantly higher concordance with histopathological findings in index tumor localization (76.5% vs. 67.9%, p < 0.001). An exploratory analysis revealed a potential age-dependent pattern, but this requires confirmation in larger studies.

Conclusions

In this select cohort, PSMA PET/CT demonstrated greater accuracy than MRI for locoregional staging in patients with intermediate-to-high-risk prostate cancer (PCa). However, the generalizability of these findings is limited by the retrospective design and potential selection bias. These results suggest that PSMA PET/CT may have a valuable role in the initial staging workflow, but this needs to be confirmed in larger, prospective studies. An exploratory analysis suggested a potential age-dependent pattern, but this requires confirmation in larger studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsPositron Emission Tomography Computed TomographyGlutamate Carboxypeptidase IIAntigens, SurfaceMagnetic Resonance ImagingHumansMaleNeoplasm StagingRetrospective StudiesMiddle AgedAgedProstatectomy

Stichwörter der Autor:innen

PSMA PET/CTdiagnostic accuracyextraprostatic extensionmagnetic resonance imaging (MRI)prostate cancerradical prostatectomyseminal vesicle invasionstaging

Substanzen

Glutamate Carboxypeptidase IIFOLH1 protein, humanAntigens, Surface

Autor:innen und Institutionen

  • Urology Department, Clínica Universidad de Navarra, 31008 Pamplona, Spain.
  • Department of Preventive Medicine, Clínica Universidad de Navarra, 31008 Pamplona, Spain.
  • Department of Health Sciences, Public University of Navarra, 31008 Pamplona, Spain.
  • Group of Clinical Epidemiology, Area of Epidemiology and Public Health, Healthcare Research Institute of Navarre (IdiSNA), 31008 Pamplona, Spain.
  • CIBER in Epidemiology and Public Health (CIBERESP), Institute of Health Carlos III, 46980 Madrid, Spain.
  • Urology Department, Clínica Universidad de Navarra, 28027 Madrid, Spain.

ORCID-Profile: Vanessa Talavera Cobo, Andres Calva Lopez, Carmina Alejandra Muñoz Bastidas, Luis Labairu Huerta, Daniel Sanchez Zalabardo, Francisco Guillen-Grima, Jose E Robles García, Bernardino Miñana-López

Zitieren

APA

Talavera Cobo, V., Yánez Ruiz, C. A., Tapia Tapia, M. D., Calva Lopez, A., Muñoz Bastidas, C. A., Ancizu Marckert, F. J., Torres Roca, M., Huerta, L. L., Sanchez Zalabardo, D., Diez-Caballero Alonso, F. J., Guillen-Grima, F., Robles García, J. E., & Miñana-López, B. (2026). Diagnostic Accuracy of PSMA-PET/CT vs. mpMRI in Primary Staging of Intermediate- and High-Risk Prostate Cancer. Medical Sciences. https://doi.org/10.3390/medsci14010064

Vancouver

Talavera Cobo V, Yánez Ruiz CA, Tapia Tapia MD, Calva Lopez A, Muñoz Bastidas CA, Ancizu Marckert FJ, et al. Diagnostic Accuracy of PSMA-PET/CT vs. mpMRI in Primary Staging of Intermediate- and High-Risk Prostate Cancer. Medical Sciences. 2026. doi:10.3390/medsci14010064

BibTeX
@article{TalaveraCobo2026,
  author = {Talavera Cobo, Vanessa and Yánez Ruiz, Carlos Andres and Tapia Tapia, Mario Daniel and Calva Lopez, Andres and Muñoz Bastidas, Carmina Alejandra and Ancizu Marckert, Francisco Javer and Torres Roca, Marcos and Huerta, Luis Labairu and Sanchez Zalabardo, Daniel and Diez-Caballero Alonso, Fernando Jose and Guillen-Grima, Francisco and Robles García, Jose E and Miñana-López, Bernardino},
  title = {Diagnostic Accuracy of PSMA-PET/CT vs. mpMRI in Primary Staging of Intermediate- and High-Risk Prostate Cancer},
  journal = {Medical Sciences},
  year = {2026},
  doi = {10.3390/medsci14010064}
}
Kostenlos starten →